NCT00807794

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

Phase I Evaluation of the Pharmacokinetics, Pharmacodynamics and Safety of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: MedImmune LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the clinical safety of different doses of MEDI-507 through day 33.

Detailed description

To evaluate the pharmacokinetic characteristics of MEDI-507 given in dose intervals.

Conditions

• Kidney Diseases

Interventions

Type	Name	Description
DRUG	MEDI-507	0.012 mg/kg dose given twice between 60 to 72 hours apart
DRUG	MEDI-507	0.06 mg/kg dose given twice between 60 to 72 hours apart
DRUG	MEDI-507	0.12 mg/kg dose given twice between 60 to 72 hours apart
DRUG	MEDI-507	0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
DRUG	MEDI-507	0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)

Timeline

• Start date: 1997-02-01
• Primary completion: 1997-11-01
• Completion: 1998-01-01
• First posted: 2008-12-12
• Last updated: 2008-12-12

Locations

4 sites across 1 country: United States